IM Therapeutics is developing a personalized, orally available small molecule therapeutic for diabetes.

The U.S. Food and Drug Administration approved Eli Lilly’s Lyumjev (insulin lispro-aabc injection, 100 units/mL and 200 units/mL), a new rapid-acting insulin indicated to improve glycemic control in adults with type 1 and type 2 diabetes.

The U.S. Food and Drug Administration cleared a new version of Abbott Laboratories’ continuous glucose monitoring device.

Two weeks after announcing concerns about high-levels of carcinogens in popular diabetes drugs, the U.S. Food and Drug Administration announced the first voluntary recalls of this class of drugs manufactured by five companies.

New Klick Health research published in Nature Digital Medicine says physicians could get a more comprehensive view of their patients’ health – and even help predict chronic disease early by assessing the interdependence of their health indicators and the body’s homeostasis system that controls them.

Diabetes and obesity remain a problem, even during a pandemic. Eli Lilly is developing 13 diabetes drugs in Phase I through Phase III trials, with data from various trials planned for release throughout 2020.

The U.S. Food and Drug Administration issued a Completed Response Letter of Eli Lilly and Boehringer Ingelheim’s Jardiance (empaglifozin) for type 1 diabetes.

The Bloc’s Dan Sontupe explores why the failure to educate patients about their conditions and treatment plans is a far bigger driver of healthcare costs than the price of prescription drugs.

Researchers at the University of Pennsylvania School of Medicine found that certain changes in DNA sequences can trigger the resulting genome to misfold in such a way that the person is at increased risk for Type 1 diabetes.

Clarivate Analytics pegged 11 drugs set to enter the market during 2020 as potential blockbusters by 2024